Here are the 424B prospectus supplements from Foghorn Therapeutics Inc. (FHTX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow FHTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FHTX filings page.
Foghorn Therapeutics is raising approximately $50 million by offering 2,030,314 shares of common stock, pre-funded warrants for 5,421,250 shares, and Series warrants to purchase up to 7,451,564 shares of common stock. The common stock is priced at $6.71 per share and the pre-funded warrants at $6.7099, with gross proceeds of about $50.0 million and estimated net proceeds of $49.6 million after expenses. The securities are sold directly to investors without underwriters.
Each share or share underlying a pre-funded warrant is paired with a Series 1 warrant and a Series 2 warrant, each to buy one-half share, with initial exercise prices of $13.42 and $20.13 per share, respectively. Foghorn expects to use the net proceeds to advance its clinical and preclinical programs and for general corporate purposes. As of September 30, 2025, the company had 56,542,877 shares outstanding, and the transaction is expected to cause immediate and substantial dilution of $8.01 per share to new investors based on that date’s adjusted net tangible book value.